Response Biomedical, Roche to take CV tests to North America
This article was originally published in Clinica
Roche Diagnostics is set to take Response Biomedical’s line of cardiovascular point-of-care tests to the North American market. The two firms have entered an exclusive agreement that will see Roche make Response’s RAMP 200 (rapid analyte measurement platform) tests for Troponin-I, CK-MB, Myoglobin and NT-proBNP available in the US, Canadian and other unnamed markets. According to Roche, the RAMP tests provide physicians with what it calls improved “vein-to-brain” time, allowing faster treatment times. Roche had previously gained worldwide rights to the line in June for an undisclosed fee. Financial details of this deal were also not revealed.